Skip to main content

20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

Written by Customer Service on . Posted in Public Companies.

2020 BioLabs Nasdaq Tower

GAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) — 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced today that it will hold a virtual investor webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time.

20/20 BioLabs President and CEO Jonathan Cohen will host the webinar to discuss the company’s recent Nasdaq listing, OneTest™ for Cancer™ AI powered multi-cancer early detection (“MCED”) blood test, One Test for Longevity™ expected to be launched before the end February, ongoing initiatives, and upcoming milestones. A question-and-answer session will follow.

Virtual Investor Webinar

February 26, 2026
2:00 p.m. Eastern Time
Webcast and Presentation:
https://us02web.zoom.us/webinar/register/WN_PCF8MVQOTEakBLccjP3ePg

A webcast replay link will be available following the call and can be found at https://ir.2020biolabs.com/.

Investors who would like to submit their questions in advance can do so by sending them to AIDX@mzgroup.us.

On February 19, 2026, 20/20 BioLabs was listed and began trading on the Nasdaq under the ticker symbol “AIDX.”

About 20/20 BioLabs

20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest’s affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.

20/20 BioLabs’ pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab. The Company’s legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. For more information visit 2020biolabs.com.

Investor Relations 
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63c41350-2f7f-4281-adcc-98f27c452c8c

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.